Viatris Inc (VTRS)vsZoetis Inc (ZTS)
VTRS
Viatris Inc
$18.97
-1.30%
HEALTHCARE · Cap: $21.56B
ZTS
Zoetis Inc
$82.11
-7.95%
HEALTHCARE · Cap: $32.15B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 55% more annual revenue ($14.74B vs $9.53B). ZTS leads profitability with a 27.7% profit margin vs -2.8%. VTRS appears more attractively valued with a PEG of 3.41. ZTS earns a higher WallStSmart Score of 58/100 (C).
VTRS
Hold42
out of 100
Grade: D
ZTS
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-81.6%
Fair Value
$8.88
Current Price
$18.97
$10.09 premium
Margin of Safety
+10.3%
Fair Value
$143.36
Current Price
$82.11
$61.25 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Every $100 of equity generates 83 in profit
Strong operational efficiency at 40.7%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
4.9% revenue growth
Expensive relative to growth rate
ROE of -2.9% — below average capital efficiency
Earnings declined 70.6%
Trading at 10.8x book value
1.2% earnings growth
Expensive relative to growth rate
Revenue declined 0.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : VTRS
The strongest argument for VTRS centers on Price/Book.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 27.7% and operating margin at 40.7%.
Bear Case : VTRS
The primary concerns for VTRS are Revenue Growth, PEG Ratio, Return on Equity.
Bear Case : ZTS
The primary concerns for ZTS are Price/Book, EPS Growth, PEG Ratio. Debt-to-equity of 2.93 is elevated, increasing financial risk.
Key Dynamics to Monitor
VTRS profiles as a turnaround stock while ZTS is a declining play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.86 — expect wider price swings.
VTRS is growing revenue faster at 4.9% — sustainability is the question.
ZTS generates stronger free cash flow (538M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (58/100 vs 42/100), backed by strong 27.7% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?